Navigation Links
GeoVax Presents Data at AIDS Vaccine 2008 Conference
Date:10/16/2008

ATLANTA, Oct. 16 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based, publicly traded biopharmaceutical company specializing in the prevention and treatment of infectious diseases, presented data on their AIDS vaccine (trial HVTN 065) at the AIDS Vaccine 2008 conference, on October 15 in Cape Town, South Africa. This conference comes at an exciting time for GeoVax, which is preparing to enter Phase 2 trials for its vaccine.

The presentation, titled "Two HIV DNA Primes Maximize T Cell Responses Induced by the GeoVax DNA/MVA Vaccine Regimen Administered to Healthy Seronegative Adults (HVTN 065)," was given by Dr. Paul A. Goepfert, M.D., Associate Professor, Division of Infectious Diseases, Department of Medicine, University of Alabama. Dr. Goepfert is the HVTN 065 Protocol Team chair. The trial results reveal the GeoVax DNA and MVA vaccines are safe and immunogenic (stimulate anti-HIV/AIDS immune responses) at both low (1/10th) dose and full doses. Other highlights included:

-- GeoVax vaccines were well tolerated with no or mild local and systemic reactions in the majority of trial participants.

-- 80 percent of both the low and full dose trial participants responded to the vaccine which stimulated anti-HIV T-cell (white blood cell) and antibody responses.

-- More volunteers had antibody responses to the full dose than to the 1/10th dose vaccine, whereas response rates for T cells were similar for the 1/10th and full dose.

-- Two DNA primes were more effective than one DNA prime or no DNA primes at eliciting T cell responses.

-- The 2nd MVA vaccination positively increased CD8 T cell and antibody responses.

"As the entire world tries to find a solution for the HIV/AIDS crisis, GeoVax, a front runner in the search for an effective vaccine, is on the verge of entering Phase 2 trials," said Bob McNally, CEO and President of GeoVax Labs, Inc. "The AIDS Vaccine 2008 conference is a
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
7. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
9. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
10. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
11. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... one of the most promising technologies for future quantum ... (photons) instead of electrons. First, it is necessary to ... and control their direction. Researchers around the world have ... but now scientists at the Niels Bohr Institute have ... one at a time and in a particular direction. ...
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... Research “Global Orthobiologics Market” the global orthobiologics market was valued ... reach a market worth USD 5,519.9million in 2019at a CAGR ... the population aged 50 years and above is afflicted by ... almost double by the year 2020. This has and will ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the six months ended ... expressed in Canadian dollars and presented under International ... 2014 Highlights , Announced top-line results ... primary endpoint for subjects enrolled in the Phase ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Three ... Energy's 2014 Hydrogen Production R&D Award ... by splitting water using sunlight. , Shared with ... and the University of Nevada, Las Vegas (UNLV), ... developing models of photoelectrochemical solar-hydrogen production and corrosion ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2
... INDIANAPOLIS, Sept. 23 The volume of biological samples ... pharmaceutical and biotechnology industries shift their focus from traditional ... and biomarkers in the discovery process has put an ... the practices that life sciences companies employ to collect, ...
... Pharmaceutical and Biotech Trainers (SPBT) today announced that Kevin ... October 1.  He brings to his new role significant ... Mr. Kruse will be responsible for leading ... organization that represents more than 1,000 members in the ...
... 23, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 2BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 3Kevin Kruse Named Executive Director of the Society of Pharmaceutical and Biotech Trainers 2BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 2BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 3BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 4BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 5BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 6BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 7
(Date:8/31/2014)... not busy attacking us, germs go after each other. ... disaster for the infected microbes: Sometimes viruses actually carry ... expand its diet or better attack its own hosts. ... immune system would robotically destroy anything it recognized as ... have now revealed that one variety of the bacterial ...
(Date:8/31/2014)... Climate Change , suggests that if current trends continue ... global targets for total greenhouse gas (GHG) emissions in 2050. ... carefully about the food we choose and its environmental impact. ... one of a number of actions that need to be ... enough food for all. , As populations rise and ...
(Date:8/31/2014)... in French . ... in the prestigious Nature Neuroscience journal by, Sylvain ... the Douglas Mental Health University Institute and McGill University, opens ... dynamic mechanisms controlling memory as well of the role of ... the subiculum. , In 2009, they developed a unique ...
Breaking Biology News(10 mins):Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2
... genome-wide association study published today in Nature Genetics ... in eight blood measurements and the impact those variants ... the number and volume of cells in the blood, ... disorders, including anaemia, infection and blood cell cancers. ...
... of human papillomavirus is seen across the population of India, ... vaccination targeting these types could eliminate 75 percent of the ... the American Association for Cancer Research Frontiers in Basic Cancer ... the most common cancer among Indian women, with an estimated ...
... across the Panama Canal in a Boston Whaler may sound ... of this story brandishes a butterfly net and studies the ... Tropical Research Institute. , "Our long-term study shows ... migrations," said Robert Srygley, former Smithsonian post doctoral fellow who ...
Cached Biology News:Blood counts are clues to human disease 2Blood counts are clues to human disease 3Scientists identify common HPV genotypes in northern India, encourage vaccination 2Panama butterfly migrations linked to El Nio, climate change 2
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
96 Well Base Plate...
... Inhibitor is a potent noncompetitive ... as RNase A. Like other ... Inhibitor is an acidic protein ... kDa. RNaseOUT inhibits RNase A ...
... and Recombinant RNasin Ribonuclease Inhibitors have broad ... of eukaryotic RNases of the neutral type ... effect by noncovalently binding to RNases in ... the binding of RNasin Ribonuclease Inhibitor to ...
Biology Products: